User login
Key clinical point: Real-world analysis confirms the safety and efficacy of trifluridine/tipiracil observed in phase 3 studies in metastatic colorectal cancer (mCRC).
Major finding: The median overall survival and progression-free survival was 7.6 (95% confidence interval [CI], 6.5-8.6) months and 3.3 (95% CI, 3.03-3.57) months, respectively. The objective response rate and disease control rate were 2.4% and 24.0%, respectively. The most frequent grade 3 toxicities included neutropenia (37%), fatigue (10%), anemia (9%), and febrile neutropenia (5%). Overall, 27% of patients required dose reduction mainly because of hematological toxicities (60%).
Study details: This was a retrospective analysis of 236 patients with chemotherapy refractive mCRC who received at least 1 dose of trifluridine/tipiracil as third-line treatment.
Disclosures: The study did not declare any source of funding. Some of the authors including the lead author declared receiving research funding, travel and accommodation expenses, honoraria, and/or lecture fees from and/or served in consulting or advisory roles for various sources.
Source: Stavraka C et al. Clin Colorectal Cancer. 2021 Sep 26. doi: 10.1016/j.clcc.2021.09.009.
Key clinical point: Real-world analysis confirms the safety and efficacy of trifluridine/tipiracil observed in phase 3 studies in metastatic colorectal cancer (mCRC).
Major finding: The median overall survival and progression-free survival was 7.6 (95% confidence interval [CI], 6.5-8.6) months and 3.3 (95% CI, 3.03-3.57) months, respectively. The objective response rate and disease control rate were 2.4% and 24.0%, respectively. The most frequent grade 3 toxicities included neutropenia (37%), fatigue (10%), anemia (9%), and febrile neutropenia (5%). Overall, 27% of patients required dose reduction mainly because of hematological toxicities (60%).
Study details: This was a retrospective analysis of 236 patients with chemotherapy refractive mCRC who received at least 1 dose of trifluridine/tipiracil as third-line treatment.
Disclosures: The study did not declare any source of funding. Some of the authors including the lead author declared receiving research funding, travel and accommodation expenses, honoraria, and/or lecture fees from and/or served in consulting or advisory roles for various sources.
Source: Stavraka C et al. Clin Colorectal Cancer. 2021 Sep 26. doi: 10.1016/j.clcc.2021.09.009.
Key clinical point: Real-world analysis confirms the safety and efficacy of trifluridine/tipiracil observed in phase 3 studies in metastatic colorectal cancer (mCRC).
Major finding: The median overall survival and progression-free survival was 7.6 (95% confidence interval [CI], 6.5-8.6) months and 3.3 (95% CI, 3.03-3.57) months, respectively. The objective response rate and disease control rate were 2.4% and 24.0%, respectively. The most frequent grade 3 toxicities included neutropenia (37%), fatigue (10%), anemia (9%), and febrile neutropenia (5%). Overall, 27% of patients required dose reduction mainly because of hematological toxicities (60%).
Study details: This was a retrospective analysis of 236 patients with chemotherapy refractive mCRC who received at least 1 dose of trifluridine/tipiracil as third-line treatment.
Disclosures: The study did not declare any source of funding. Some of the authors including the lead author declared receiving research funding, travel and accommodation expenses, honoraria, and/or lecture fees from and/or served in consulting or advisory roles for various sources.
Source: Stavraka C et al. Clin Colorectal Cancer. 2021 Sep 26. doi: 10.1016/j.clcc.2021.09.009.